Stanford big data techno-optimist and internist Russ Altman shows us how the power of machine learning in drug development is helping us understand adverse medication effects.
Share this post
Latest News posts
Nasilele Simukulva: Chronic Pulmonary Aspergillosis
January 29, 2019
Stephen Entwistle: Chronic Pulmonary Aspergillosis
January 29, 2019
Jacqueline: Chronic Pulmonary Aspergillosis
January 29, 2019
John Guto: Chronic Pulmonary Aspergillosis
January 29, 2019
Breaking Thought Cycles Using Mindfulness
January 29, 2019
Prescribe Happiness to Improve Our Health
January 29, 2019
What Happens When Patients Lead the Health Team?
January 29, 2019
Getting a grip on pain and the brain: Prof Lorimer Moseley
January 29, 2019
All day in hospital
January 29, 2019
How to produce a sputum sample when asked
January 29, 2019
News archive
× Close
- Antifungals in development
- COVID-19
- Events
- Fundraising
- General interest
- How do I...?
- Information and Learning
- Latest research news
- Lifestyle and Coping Skills
- Living with Aspergillosis
- NAC announcements
- News archive
- Patient and Carer Blog
- Patient stories
- Recordings
- Supplements and complementary therapies
- Types of aspergillosis
- Video